Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
Both Commit to Continuous Advancements in Urology Research and Education
ORLANDO, Fla., May 16, 2014 /PRNewswire/ -- The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA), and Allergan, Inc. (NYSE: AGN) today announced the launch of two programs at the American Urological Association Annual Meeting May 16-21 in Orlando, FL, to support the Urology Care Foundation's effort in advancing urology research and patient education.
"We value and are encouraged by Allergan's commitment to supporting the Foundation's mission of fostering the highest standards of urologic care through research and education," said Richard Memo, M.D., Chair, Board of Directors, Urology Care Foundation. "The support from, and collaboration with, Allergan will help us better integrate the patient voice into the annual meeting and elevate the dialogue about patient education, care and access."
Allergan is one of the leading sponsors of the inaugural "Voices of Urology Patient Advocacy Hub." Through "Voices of Urology," Urology Care Foundation will provide non-profit organizations with complimentary exhibit space and sessions highlighting research presented at the meeting. The program will offer heightened visibility to patient advocacy group thought leaders, and greater exposure of the resources available through these organizations for urology patients. Allergan will also make an additional contribution to the Urology Care Foundation of up to $25,000 through a special program in the Allergan booth during the annual meeting.
"Allergan is committed to providing educational resources that help patients make good decisions and gain access to the most advanced treatments," said Julian Gangolli, Allergan Corporate Vice President and President, North America. "We are proud to support the Urology Care Foundation and its efforts to promote education and to help improve the quality of life for urology patients."
About the Urology Care Foundation
The Urology Care Foundation is committed to advancing urology research and education. We work with researchers, health care professionals, patients, and caregivers to improve patients' lives. The Urology Care Foundation is the official foundation of the American Urological Association (AUA).
About the AUA
Founded in 1902, the AUA is a leading advocate for the specialty of urology, and has more than 20,000 members worldwide. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,600 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.
This press release contains "forward-looking statements," including but not limited to, the statements by Dr. Richard Memo and Julian Gangolli. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; challenges related to achieving regulatory approval from the FDA on a timely and cost-efficient manner; technological advances and patents attained by competitors; inconsistency of treatment results among patients; potential difficulties in manufacturing; challenges related to new product marketing, such as the unpredictability or market acceptance for new products and/or the acceptance of new indications for such products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risks can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.
Urology Care Foundation Contact
Christine Frey, 410-999-7091; cfrey@AUAnet.org
©2014 Allergan, Inc. Irvine, CA 92612. ® marks owned by Allergan, Inc. All rights reserved.
©2012 PR Newswire. All Rights Reserved.